News, much of it good, keeps coming in about the efficacy of the various COVID-19 vaccines. Here’s a look.
Although yesterday’s media focus was on the riots at the U.S. Capitol, there was a fair amount of ongoing COVID-19 news. Here’s a look.
Keeping in mind that COVID-19 has dominated the news cycle, here are the top 10 stories of 2020 in no particular order.
In a recent paper published in Alzheimer’s and Dementia, a team of researchers is calling for more prospective studies that will look into the impact coronavirus disease 2019 (COVID-19) has on brain functioning.
SARS-CoV-2 has mutated into several strains. Most of them are not particularly different than the primary strains, but two, B.1.1.7, which was first observed in the U.K., and now 501.V2, which originated in South Africa, have virologists watching closely.
The U.S. FDA came out to warn health care personnel not to make any changes to the dosing of the vaccines and that doing so would place the public health at risk and undermine “the historic vaccination effort to protect the population.”
With COVID-19 still running rampant across the globe, Moderna announced it will rapidly expand its vaccine manufacturing operations in order to meet demand in the countries where the medication has received emergency authorization.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for January 5, 2021.
From synthetic polymer-based anti-infectives to antiviral conjugates and DNA vaccines, the past year has given new and emerging drug classes an opportunity to shine.
As Operation Warp Speed struggles to ramp up vaccinations, one of the approaches under consideration is cutting the doses of the Moderna vaccine.
It’s not particularly surprising that there wasn’t a lot of clinical trial news between Christmas and New Year’s, although there was some. Here’s a look.
Over the course of 2020, the biopharmaceutical industry came together to rapidly address the global COVID-19 crisis. Despite that spirit of comradery and partnership, there were still a few incidents that caused some arched eyebrows, gasps of astonishment and even fits of anger.
The U.K authorized AstraZeneca’s COVID-19 vaccine on Wednesday, but it could be April at the earliest before the drug will likely be administered in the United States, Operation Warp Speed’s chief said.
If 2020 taught us anything, it was that unexpected things happen. That said, there are some stories we’ll be watching for. Here’s a look.
Overnight, U.K. health authorities authorized the COVID-19 vaccine developed by AstraZeneca and Oxford University for emergency use.
Operation Warp Speed succeeded on the development component, but is failing in the early stages of distribution.
Sinopharm, a Chinese biopharmaceutical company controlled by the state, announced that its COVID-19 vaccine candidate had an efficacy rate of 79% based on interim analysis of Phase III trials.
A great deal remains unknown about the SARS-CoV-2 virus, its mutations, transmissibility and long-term effects. Here’s what we do know.
The U.S. Department of Defense awarded Moderna a contract worth $1,966,598,000 for an additional 100 million doses of its COVID-19 vaccine.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for December 29, 2020.